In this latest whitepaper, we describe the next generation vector technology, Nanoplasmids, to support the growing demand of plasmid DNA production, performance, and regulatory guidelines. Utilizing the small backbone with its patented, non-antibiotic selection can be key in a successful clinical program. Implementing the Nanoplasmid technology not only increases manufacturing, transfection viability, and transgene expression but also reduces safety concerns. We describe recent publications demonstrating how this tool can improve non-viral gene delivery therapies, such as CRISPR homology directed repair (HDR). Overall, the Nanoplasmid vector technology is a proven approach to maximize the initial building material for a wide range of cell and gene therapies. |
